stat6

AS1517499 is a potent STAT6 inhibitor with IC50 of 21 nM

STAT6-IN-1, a STAT6 inhibitor, exhibits high affinity for the SH2 domain of STAT6 (IC 50 = 0.028 µM), making it suitable for research on allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease, or cancer.

STAT6-IN-2 (Comp R-84) is a STAT6 inhibitor that effectively reduces the secretion of the chemokine eotaxin-3, which induces eosinophil infiltration. This compound is valuable for studying immune diseases [1].

STAT6-IN-3 (Compound 18a) is an inhibitor of STAT6, targeting the Src Homology 2 (SH2) domain with an IC50 value of 44 nM. It is used in research on inflammatory disorders, such as asthma [1].

STAT6-IN-5 (34) is an inhibitor of STAT6 with an IC50 of 0.24 μM.

STAT6-IN-4 (78) functions as a STAT6 inhibitor, exhibiting an IC50 value of 0.34 μM.

IL-4 inhibitor is an inhibitor of IL-4.1It binds to IL-4 with a Kdvalue of 1.8 μM and inhibits IL-4 activity in a cell-based reporter assay (EC50= 1.81 μM). It is selective for IL-4 over IL-13 (EC50= 18.2 μM). IL-4 inhibitor inhibits IL-4-induced STAT6 phosphorylation in THP-1 monocytes (EC50= 3.1 μM), indicating inhibition of the IL-4-JAK1-STAT6 signaling pathway.

AK-068 is a STAT6 ligand with a Ki value of 6 nM, exhibiting at least 85-fold higher selectivity in binding to STAT6 over STAT5.

AK-1690 is a potent and selective STAT6 PROTAC degrader that induces degradation of STAT6 proteins in cells (DC50=1 nM) and depletes STAT6 proteins in mouse tissues, which can be used in cancer research.

7-Bromohept-1-yne is a PROTAC Linker that can be used to synthesize AK-1690, a STAT6 (Signal transducer and activator of transcription 6) PROTAC degradator.

SD-436 is a highly selective and efficient STAT3 PROTAC degrader, with a DC50 of 0.5 μM. It exhibits IC50 values of 19 nM for STAT3, 270 nM for STAT1, 360 nM for STAT4, and >10 μM for both STAT5 and STAT6. SD-436 promotes the ubiquitination and degradation of STAT3, and it induces tumor regression. This compound is applicable for tumor research, including studies on leukemia and lymphoma.

YM-341619 (AS1617612) is a potent, orally active STAT6 inhibitor (IC50: 0.70 nM) that inhibits IL-4-induced Th2 differentiation in mouse splenic T cells with an IC50 value of 0.28 nM, without affecting Th1 cell differentiation. YM-341619 holds potential for research into allergic diseases, such as allergic asthma.

PM-43I is a potent inhibitor of both STAT5- and STAT6-dependent allergic airway disease in mice.

PM-81I, a potent STAT6 inhibitor targeting the SH2 structural domain, effectively reduces STAT6 phosphorylation levels. It is applicable in the research of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease, or cancer [1].

Rademikibart (CBP-201) is a human monoclonal antibody selective for IL-4Rα, exhibiting strong affinity with a KD of 20.7 pM for human IL-4Rα epitopes, without cross-reactivity to IL-4Rα from other species. It effectively inhibits IL-4 and IL-13-induced STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMCs, showing promise for investigating moderate-to-severe Th2 inflammatory diseases [1].

AS1810722, a fused bicyclic pyrimidine derivative, is an orally active and potent inhibitor of STAT6, demonstrating an IC50 of 1.9 nM. It exhibits effective inhibition of CYP3A4, positioning it as a promising candidate for research into allergic diseases, including asthma and atopic conditions.

7,4'-Dihydroxyflavone (4',7-Dihydroxyflavone) can induce transcription of nodulation (nod) genes in Rhizobium meliloti. It has inhibitory activities against COX-2.